首页 > 最新文献

Journal of Pharmaceutical Health Care and Sciences最新文献

英文 中文
Evaluation of a joint workshop on study design for hospital and community pharmacists: a retrospective cross-sectional survey. 医院和社区药剂师研究设计联合研讨会评估:回顾性横断面调查。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-04 DOI: 10.1186/s40780-024-00337-x
Yuki Asai, Yasushi Takai, Toshiki Murasaka, Tomohiro Miyake, Tomohisa Nakamura, Yoshihiko Morikawa, Yuji Nakagawa, Tatsuya Kanayama, Yasuharu Abe, Naoki Masuda, Yasushi Takamura, Yoshihiro Miki, Takuya Iwamoto

Background: Although pharmacists often identify numerous clinical questions, they face several barriers, including the lack of mentors for research activities in clinical settings. Therefore, a workshop for the appropriate selection of a study design, which is a fundamental first step, may be necessary. The purpose of this study was to evaluate the effectiveness of a workshop on study design for hospital and community pharmacists. Moreover, the characteristics of pharmacists with little involvement in research activities were extracted using decision-tree analysis to guide the design of future workshops.

Methods: A workshop was conducted on October 1, 2023. It comprised three parts: lectures, group work, and presentations. Questionnaire-based surveys were conducted with workshop participants regarding their basic information, their background that influenced research activities, their satisfaction, and their knowledge/awareness. For the questions on knowledge/awareness, the same responses were requested before and after the workshop using a five-scale scoring system. Multivariate logistic regression analysis was conducted to identify independent factors influencing research activities. Decision tree analysis was performed to extract low-effort characteristics of the research activities.

Results: Of the 40 workshop attendees, the overall satisfaction score for the workshop was 4.38 of 5, and the score for each question was 4 or higher. Significant increases were observed in the scores of knowledge/awareness after the workshop. Moreover, 95% of the pharmacists answered that it would be highly useful to conduct a joint workshop between hospitals and community pharmacists. Although independent influencing factors were not detected in the multivariate logistic regression analysis, the decision tree analysis revealed that pharmacists who were no member of an academic society (85%, 11/13) or members without any certifications or accreditations related to pharmacy practice (80%, 4/5) were the least active in clinical research. In contrast, those belonging to academic societies and holding certifications or accreditations related to pharmacy practice frequently conducted clinical research.

Conclusion: The present study revealed that a joint workshop on study design may have the potential to change pharmacists' knowledge and awareness of research activities. Moreover, future workshops should be conducted with pharmacists who do not belong to academic societies.

背景:虽然药剂师经常会发现许多临床问题,但他们面临着一些障碍,包括缺乏临床研究活动的指导者。因此,可能有必要举办一个研讨会,以适当选择研究设计,这是基本的第一步。本研究旨在评估为医院和社区药剂师举办的研究设计研讨会的效果。此外,还利用决策树分析法提取了很少参与研究活动的药剂师的特点,以指导今后研讨会的设计:研讨会于 2023 年 10 月 1 日举行。研讨会由三个部分组成:讲座、小组合作和演讲。对研讨会参与者进行了问卷调查,内容包括他们的基本信息、影响研究活动的背景、他们的满意度以及他们的知识/意识。对于知识/意识方面的问题,采用五级评分法要求学员在研修班前后做出相同的回答。进行了多元逻辑回归分析,以确定影响研究活动的独立因素。此外,还进行了决策树分析,以提取研究活动的低强度特征:在 40 名研修班学员中,研修班的总体满意度为 4.38 分(满分为 5 分),每个问题的得分都在 4 分或以上。研修班结束后,药剂师的知识/认知度得分明显提高。此外,95% 的药剂师回答说,举办医院与社区药剂师联合工作坊非常有用。虽然在多元逻辑回归分析中未发现独立的影响因素,但决策树分析显示,非学术团体成员(85%,11/13)或未获得任何与药学实践相关的认证或资格的成员(80%,4/5)的药剂师在临床研究中最不活跃。相比之下,那些属于学术团体并持有与药学实践相关的认证或资格证书的医师则经常开展临床研究:本研究表明,关于研究设计的联合研讨会有可能改变药剂师对研究活动的了解和认识。此外,今后应与不属于学术团体的药剂师共同举办研讨会。
{"title":"Evaluation of a joint workshop on study design for hospital and community pharmacists: a retrospective cross-sectional survey.","authors":"Yuki Asai, Yasushi Takai, Toshiki Murasaka, Tomohiro Miyake, Tomohisa Nakamura, Yoshihiko Morikawa, Yuji Nakagawa, Tatsuya Kanayama, Yasuharu Abe, Naoki Masuda, Yasushi Takamura, Yoshihiro Miki, Takuya Iwamoto","doi":"10.1186/s40780-024-00337-x","DOIUrl":"10.1186/s40780-024-00337-x","url":null,"abstract":"<p><strong>Background: </strong>Although pharmacists often identify numerous clinical questions, they face several barriers, including the lack of mentors for research activities in clinical settings. Therefore, a workshop for the appropriate selection of a study design, which is a fundamental first step, may be necessary. The purpose of this study was to evaluate the effectiveness of a workshop on study design for hospital and community pharmacists. Moreover, the characteristics of pharmacists with little involvement in research activities were extracted using decision-tree analysis to guide the design of future workshops.</p><p><strong>Methods: </strong>A workshop was conducted on October 1, 2023. It comprised three parts: lectures, group work, and presentations. Questionnaire-based surveys were conducted with workshop participants regarding their basic information, their background that influenced research activities, their satisfaction, and their knowledge/awareness. For the questions on knowledge/awareness, the same responses were requested before and after the workshop using a five-scale scoring system. Multivariate logistic regression analysis was conducted to identify independent factors influencing research activities. Decision tree analysis was performed to extract low-effort characteristics of the research activities.</p><p><strong>Results: </strong>Of the 40 workshop attendees, the overall satisfaction score for the workshop was 4.38 of 5, and the score for each question was 4 or higher. Significant increases were observed in the scores of knowledge/awareness after the workshop. Moreover, 95% of the pharmacists answered that it would be highly useful to conduct a joint workshop between hospitals and community pharmacists. Although independent influencing factors were not detected in the multivariate logistic regression analysis, the decision tree analysis revealed that pharmacists who were no member of an academic society (85%, 11/13) or members without any certifications or accreditations related to pharmacy practice (80%, 4/5) were the least active in clinical research. In contrast, those belonging to academic societies and holding certifications or accreditations related to pharmacy practice frequently conducted clinical research.</p><p><strong>Conclusion: </strong>The present study revealed that a joint workshop on study design may have the potential to change pharmacists' knowledge and awareness of research activities. Moreover, future workshops should be conducted with pharmacists who do not belong to academic societies.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"14"},"PeriodicalIF":1.0,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10910793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140028269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vaccination status, incidence of adverse events, and awareness of COVID-19 vaccine among outpatients undergoing chemotherapy. 门诊化疗患者的疫苗接种情况、不良事件发生率以及对 COVID-19 疫苗的认识。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-04 DOI: 10.1186/s40780-024-00338-w
Satoshi Iwakawa, Takuya Azechi, Orie Saigo, Ryunosuke Imai, Ayumi Nakai, Shoji Koshiba, Uki Saito, Kota Asakura, Kuniyoshi Sato, Toshimi Kimura

Background: Cancer has been identified as a risk factor for severe illness and mortality in coronavirus disease (COVID-19), underscoring the importance of recommending COVID-19 vaccinations to patients with cancer. However, few reports have focused on the vaccination status and the incidence of adverse events among patients with cancer. In this study, we aimed to evaluate the vaccination status, incidence of adverse events, concerns, and anxiety related to COVID-19 vaccination among patients with cancer. In addition, we explored the utilization of information sources by these patients and the ease of use.

Methods: A survey was conducted among outpatients undergoing chemotherapy who received medication counseling from a pharmacist at Juntendo University Hospital. Responses were gathered from 60 out of the 143 participants. Of the respondents, 96.7% had received two doses of the COVID-19 vaccine.

Results: Common adverse events included pain at the injection site, fever, and fatigue, which were experienced by nearly half of the respondents. Approximately 80% expressed some concern regarding vaccination, with predominant concerns about timing in the context of ongoing cancer treatment and surgery. Among the respondents, 41.7% consulted primary care physicians regarding the vaccine, with only one mentioning consultation with hospital pharmacists. Notably, primary care physicians were considered the most approachable and useful healthcare professionals.

Conclusions: These results suggest that patients with cancer can safely receive the vaccine, comparable to patients without cancer. However, they still harbor concerns, even when seeking advice from primary care physicians. Few patients consulted pharmacists about vaccination, highlighting an opportunity for pharmacist intervention. Pharmacists fostering trust with patients with cancer is imperative to explore pharmacist intervention methods to promote the continued administration of COVID-19 vaccines and enhance the quality of life for them.

背景:癌症已被确定为冠状病毒病(COVID-19)导致重症和死亡的一个风险因素,这突出了向癌症患者推荐接种 COVID-19 疫苗的重要性。然而,很少有报道关注癌症患者的疫苗接种情况和不良事件的发生率。在本研究中,我们旨在评估癌症患者的疫苗接种情况、不良事件发生率、与 COVID-19 疫苗接种相关的担忧和焦虑。此外,我们还探讨了这些患者对信息来源的利用情况以及使用的便捷性:方法:我们对接受顺天堂大学医院药剂师药物咨询的化疗门诊患者进行了调查。在 143 名参与者中,有 60 人做出了回答。结果显示,96.7%的受访者接种过两剂COVID-19疫苗:结果:常见的不良反应包括注射部位疼痛、发烧和疲劳,近一半的受访者都经历过这些不良反应。约 80% 的受访者对接种疫苗表示了一定的担忧,其中最主要的担忧是接种疫苗的时间是否与正在进行的癌症治疗和手术有关。在受访者中,41.7% 的人就疫苗问题咨询过初级保健医生,只有一人提到咨询过医院药剂师。值得注意的是,初级保健医生被认为是最平易近人、最有用的医疗保健专业人员:这些结果表明,癌症患者与非癌症患者一样可以安全接种疫苗。然而,即使在寻求初级保健医生的建议时,他们仍会有所顾虑。很少有患者向药剂师咨询疫苗接种事宜,这为药剂师的干预提供了机会。药剂师必须与癌症患者建立信任关系,探索药剂师干预方法,以促进COVID-19疫苗的持续接种并提高患者的生活质量。
{"title":"Vaccination status, incidence of adverse events, and awareness of COVID-19 vaccine among outpatients undergoing chemotherapy.","authors":"Satoshi Iwakawa, Takuya Azechi, Orie Saigo, Ryunosuke Imai, Ayumi Nakai, Shoji Koshiba, Uki Saito, Kota Asakura, Kuniyoshi Sato, Toshimi Kimura","doi":"10.1186/s40780-024-00338-w","DOIUrl":"10.1186/s40780-024-00338-w","url":null,"abstract":"<p><strong>Background: </strong>Cancer has been identified as a risk factor for severe illness and mortality in coronavirus disease (COVID-19), underscoring the importance of recommending COVID-19 vaccinations to patients with cancer. However, few reports have focused on the vaccination status and the incidence of adverse events among patients with cancer. In this study, we aimed to evaluate the vaccination status, incidence of adverse events, concerns, and anxiety related to COVID-19 vaccination among patients with cancer. In addition, we explored the utilization of information sources by these patients and the ease of use.</p><p><strong>Methods: </strong>A survey was conducted among outpatients undergoing chemotherapy who received medication counseling from a pharmacist at Juntendo University Hospital. Responses were gathered from 60 out of the 143 participants. Of the respondents, 96.7% had received two doses of the COVID-19 vaccine.</p><p><strong>Results: </strong>Common adverse events included pain at the injection site, fever, and fatigue, which were experienced by nearly half of the respondents. Approximately 80% expressed some concern regarding vaccination, with predominant concerns about timing in the context of ongoing cancer treatment and surgery. Among the respondents, 41.7% consulted primary care physicians regarding the vaccine, with only one mentioning consultation with hospital pharmacists. Notably, primary care physicians were considered the most approachable and useful healthcare professionals.</p><p><strong>Conclusions: </strong>These results suggest that patients with cancer can safely receive the vaccine, comparable to patients without cancer. However, they still harbor concerns, even when seeking advice from primary care physicians. Few patients consulted pharmacists about vaccination, highlighting an opportunity for pharmacist intervention. Pharmacists fostering trust with patients with cancer is imperative to explore pharmacist intervention methods to promote the continued administration of COVID-19 vaccines and enhance the quality of life for them.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"15"},"PeriodicalIF":1.0,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10913650/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140028270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Renal function and lipid metabolism in Japanese HIV-1-positive individuals 288 weeks after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate: a single-center, retrospective cohort study. 日本 HIV-1 阳性者从富马酸替诺福韦二吡呋酯转为富马酸替诺福韦阿拉非酰胺后 288 周的肾功能和脂质代谢:一项单中心回顾性队列研究。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-02-28 DOI: 10.1186/s40780-024-00336-y
Kensuke Abe, Junji Imamura, Akiko Sasaki, Tomoko Suzuki, Satomi Kamio, Taku Obara, Toshihiro Ito

Background: Continued use of tenofovir disoproxil fumarate (TDF), an antiretroviral drug, causes renal function decline and tubular damage in individuals with HIV. While tenofovir alafenamide fumarate (TAF) may have less damaging effects, it causes weight gain and abnormal lipid metabolism.

Methods: This single-center, retrospective cohort study used medical records from the National Hospital Organization Sendai Medical Center to investigate renal function of Japanese HIV-1-positive individuals who switched from TDF to antiretroviral therapy including TAF by 2017. The endpoints were: estimated glomerular filtration rate (eGFR), urinary β2 microglobulin (Uβ2MG), weight, and lipid metabolism parameters at 288 weeks after switching. Possible correlation between eGFR and Uβ2MG and factors affecting eGFR decline were examined.

Results: Sixty patients switched from TDF to TAF and continued therapy for 288 weeks. eGFR showed a significant decline after 144 weeks, although it was controlled from the time of change until 96 weeks. In the renal impairment group, the decline was suppressed until week 288. Uβ2MG continued to decrease significantly after 48 weeks. However, the suggested correlation between eGFR and Uβ2MG disappeared when patients switched from TDF to TAF. Weight and lipid metabolic parameters increased significantly at 48 weeks and were maintained. Factors associated with decreased eGFR were: history of acquired immune deficiency syndrome (AIDS) and Uβ2MG. However, considering the odds ratio, the switch from TDF to TAF suppressed the eGFR decline in the group with a history of AIDS, and Uβ2MG had no effect on the eGFR decline.

Conclusions: Switching from TDF to TAF for the long term slows eGFR decline, decreases Uβ2MG levels, and reduces worsening of renal function. Weight gain and abnormal lipid metabolism may occur in the short term but are controllable.

背景:持续使用抗逆转录病毒药物富马酸替诺福韦二吡呋酯(TDF)会导致艾滋病毒感染者肾功能下降和肾小管损伤。虽然富马酸替诺福韦阿拉非酰胺(TAF)的损害作用可能较小,但它会导致体重增加和脂质代谢异常:这项单中心、回顾性队列研究利用国立医院组织仙台医疗中心的医疗记录,调查了到 2017 年从 TDF 转为包括 TAF 在内的抗逆转录病毒疗法的日本 HIV-1 阳性患者的肾功能。研究终点为:转换疗法288周后的估计肾小球滤过率(eGFR)、尿β2微球蛋白(Uβ2MG)、体重和脂质代谢参数。研究了 eGFR 和 Uβ2MG 之间可能存在的相关性以及影响 eGFR 下降的因素:60名患者从TDF转为TAF,并继续治疗288周。144周后,eGFR出现明显下降,尽管从转药至96周期间,eGFR一直处于受控状态。在肾功能受损组,下降趋势在第288周之前一直受到抑制。48 周后,Uβ2MG 继续显著下降。然而,当患者从TDF转为TAF时,eGFR与Uβ2MG之间的相关性消失了。体重和脂质代谢参数在 48 周时明显增加并保持不变。与 eGFR 下降相关的因素有:获得性免疫缺陷综合征(艾滋病)病史和 Uβ2MG。然而,考虑到几率比,从TDF改为TAF抑制了有艾滋病史组的eGFR下降,而Uβ2MG对eGFR下降没有影响:结论:长期从 TDF 改用 TAF 可减缓 eGFR 下降,降低 Uβ2MG 水平,减少肾功能恶化。短期内可能会出现体重增加和脂质代谢异常,但可以控制。
{"title":"Renal function and lipid metabolism in Japanese HIV-1-positive individuals 288 weeks after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate: a single-center, retrospective cohort study.","authors":"Kensuke Abe, Junji Imamura, Akiko Sasaki, Tomoko Suzuki, Satomi Kamio, Taku Obara, Toshihiro Ito","doi":"10.1186/s40780-024-00336-y","DOIUrl":"10.1186/s40780-024-00336-y","url":null,"abstract":"<p><strong>Background: </strong>Continued use of tenofovir disoproxil fumarate (TDF), an antiretroviral drug, causes renal function decline and tubular damage in individuals with HIV. While tenofovir alafenamide fumarate (TAF) may have less damaging effects, it causes weight gain and abnormal lipid metabolism.</p><p><strong>Methods: </strong>This single-center, retrospective cohort study used medical records from the National Hospital Organization Sendai Medical Center to investigate renal function of Japanese HIV-1-positive individuals who switched from TDF to antiretroviral therapy including TAF by 2017. The endpoints were: estimated glomerular filtration rate (eGFR), urinary β2 microglobulin (Uβ2MG), weight, and lipid metabolism parameters at 288 weeks after switching. Possible correlation between eGFR and Uβ2MG and factors affecting eGFR decline were examined.</p><p><strong>Results: </strong>Sixty patients switched from TDF to TAF and continued therapy for 288 weeks. eGFR showed a significant decline after 144 weeks, although it was controlled from the time of change until 96 weeks. In the renal impairment group, the decline was suppressed until week 288. Uβ2MG continued to decrease significantly after 48 weeks. However, the suggested correlation between eGFR and Uβ2MG disappeared when patients switched from TDF to TAF. Weight and lipid metabolic parameters increased significantly at 48 weeks and were maintained. Factors associated with decreased eGFR were: history of acquired immune deficiency syndrome (AIDS) and Uβ2MG. However, considering the odds ratio, the switch from TDF to TAF suppressed the eGFR decline in the group with a history of AIDS, and Uβ2MG had no effect on the eGFR decline.</p><p><strong>Conclusions: </strong>Switching from TDF to TAF for the long term slows eGFR decline, decreases Uβ2MG levels, and reduces worsening of renal function. Weight gain and abnormal lipid metabolism may occur in the short term but are controllable.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"13"},"PeriodicalIF":1.0,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10900624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139990392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patients with infusion-related reactions on fixed-dose rituximab treatment have higher body surface area than those without infusion-related reactions in adults with frequently relapsing minimal change nephrotic syndrome: a retrospective study. 一项回顾性研究:在经常复发的微小病变肾病综合征成人患者中,接受固定剂量利妥昔单抗治疗后出现输液相关反应的患者的体表面积高于未出现输液相关反应的患者。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-02-22 DOI: 10.1186/s40780-024-00334-0
Hironobu Nishiura, Masaya Takahashi, Katsuhito Mori, Takashi Sugimoto, Masanori Emoto, Yasutaka Nakamura

Background: Infusion-related reactions (IRRs) are major side effects of rituximab administration. Male sex, high body weight, body surface area (BSA), and body mass index are predictive markers of rituximab-induced IRRs. However, as rituximab was not administered at a fixed dosage in a previous study, whether a higher dosage or factors associated with a larger physique are more strongly associated with rituximab-induced IRRs is unknown.

Main body: Thirteen adults with frequently relapsing minimal change nephrotic syndrome (MCNS) who received an initial rituximab dose of 500 mg between September 2015 and November 2022 were retrospectively evaluated. Data on IRRs were collected from medical records. The incidence of rituximab-induced IRRs was 38.5% (5/13). The IRR group had a significantly higher BSA than the non-IRR group (median, 1.86 vs. 1.48 m2; p = 0.045). Additionally, rituximab dosage normalized by BSA in the IRR group was significantly lower than that in the non-IRR group (median, 268.8 vs. 337.9 mg/m2; p = 0.045).

Conclusions: Our study revealed that adults with frequently relapsing MCNS who experienced IRRs tend to have a higher BSA, even with fixed-dose rituximab treatment. Therefore, when patients with higher BSA receive rituximab treatment, clinicians should be careful about monitoring patient condition whether the dosage is fixed or not.

背景输液相关反应(IRR)是利妥昔单抗用药的主要副作用。男性、高体重、体表面积(BSA)和体重指数是利妥昔单抗引起输液相关反应的预测指标。然而,由于在之前的一项研究中,利妥昔单抗的用药剂量并不固定,因此,用药剂量越大或体型越大的相关因素是否与利妥昔单抗诱发的IRR有更强的关联尚不清楚:对2015年9月至2022年11月期间接受初始剂量为500毫克利妥昔单抗治疗的13名经常复发的肾病综合征(MCNS)成人患者进行了回顾性评估。IRR数据来自医疗记录。利妥昔单抗引起的IRR发生率为38.5%(5/13)。IRR组的BSA明显高于非IRR组(中位数为1.86平方米对1.48平方米;P = 0.045)。此外,IRR组的利妥昔单抗剂量按BSA归一化后明显低于非IRR组(中位数,268.8 vs. 337.9 mg/m2; p = 0.045):我们的研究显示,频繁复发的成人 MCNS 患者在经历 IRR 后,即使接受固定剂量利妥昔单抗治疗,其 BSA 也往往较高。因此,当 BSA 较高的患者接受利妥昔单抗治疗时,无论剂量是否固定,临床医生都应注意监测患者的病情。
{"title":"Patients with infusion-related reactions on fixed-dose rituximab treatment have higher body surface area than those without infusion-related reactions in adults with frequently relapsing minimal change nephrotic syndrome: a retrospective study.","authors":"Hironobu Nishiura, Masaya Takahashi, Katsuhito Mori, Takashi Sugimoto, Masanori Emoto, Yasutaka Nakamura","doi":"10.1186/s40780-024-00334-0","DOIUrl":"10.1186/s40780-024-00334-0","url":null,"abstract":"<p><strong>Background: </strong>Infusion-related reactions (IRRs) are major side effects of rituximab administration. Male sex, high body weight, body surface area (BSA), and body mass index are predictive markers of rituximab-induced IRRs. However, as rituximab was not administered at a fixed dosage in a previous study, whether a higher dosage or factors associated with a larger physique are more strongly associated with rituximab-induced IRRs is unknown.</p><p><strong>Main body: </strong>Thirteen adults with frequently relapsing minimal change nephrotic syndrome (MCNS) who received an initial rituximab dose of 500 mg between September 2015 and November 2022 were retrospectively evaluated. Data on IRRs were collected from medical records. The incidence of rituximab-induced IRRs was 38.5% (5/13). The IRR group had a significantly higher BSA than the non-IRR group (median, 1.86 vs. 1.48 m<sup>2</sup>; p = 0.045). Additionally, rituximab dosage normalized by BSA in the IRR group was significantly lower than that in the non-IRR group (median, 268.8 vs. 337.9 mg/m<sup>2</sup>; p = 0.045).</p><p><strong>Conclusions: </strong>Our study revealed that adults with frequently relapsing MCNS who experienced IRRs tend to have a higher BSA, even with fixed-dose rituximab treatment. Therefore, when patients with higher BSA receive rituximab treatment, clinicians should be careful about monitoring patient condition whether the dosage is fixed or not.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"12"},"PeriodicalIF":1.0,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10882848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139931652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation after implementation of chemical bowel preparation for surgical site infections in elective colorectal cancer surgery and role of antimicrobial stewardship pharmacist: Retrospective cohort study. 在选择性结直肠癌手术中对手术部位感染实施化学肠道准备后的评估以及抗菌药物管理药剂师的作用:回顾性队列研究。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-02-19 DOI: 10.1186/s40780-024-00333-1
Yasuhiro Sasaki, Akira Kurishima, Chieko Miyamoto, Kenichiro Hataji, Toru Tezuka, Hideo Katsuragawa

Background: We evaluated the predictive factors for surgical site infections (SSIs) in elective colorectal cancer surgery and the role of antimicrobial stewardship (AS) pharmacists in modifying the clinical pathway.

Main body: Between February 2017 and January 2022, 414 elective colorectal cancer surgeries were performed. The results of multivariate analysis by SSI incidence were adjusted odds ratio (aOR): 0.45; 95% confidence interval (CI): 0.22-0.96 (P = 0.039) for sex (female), aOR: 0.27; 95% CI: 0.13-0.58 (P < 0.001) for laparoscopy, aOR: 0.42; 95% CI: 0.19-0.91 (P = 0.029) for chemical bowel preparation. The median (interquartile range) postoperative length of stay was 12 (10.0-18.5) vs. 10 (9.0-13.0) days before and after the clinical pathway was modified (P < 0.001).

Conclusion: The role of AS pharmacists was primarily to conduct a literature search to explore whether SSIs could be ameliorated by pharmacotherapy, coordinate the addition of chemical bowel preparation, and epidemiologically confirm their effectiveness.

背景:我们评估了择期结直肠癌手术中手术部位感染(SSI)的预测因素以及抗菌药物管理(AS)药剂师在改变临床路径中的作用:2017年2月至2022年1月期间,共进行了414例择期结直肠癌手术。按SSI发生率进行的多变量分析结果为:性别(女性)调整后的几率比(aOR):0.45;95%置信区间(CI):0.22-0.96(P = 0.039),aOR:0.27;95% CI:0.13-0.58(P 结论:强直性脊柱炎药剂师的主要职责是进行文献检索,探索药物治疗是否可以改善 SSI,协调添加化学肠道制剂,并从流行病学角度证实其有效性。
{"title":"Evaluation after implementation of chemical bowel preparation for surgical site infections in elective colorectal cancer surgery and role of antimicrobial stewardship pharmacist: Retrospective cohort study.","authors":"Yasuhiro Sasaki, Akira Kurishima, Chieko Miyamoto, Kenichiro Hataji, Toru Tezuka, Hideo Katsuragawa","doi":"10.1186/s40780-024-00333-1","DOIUrl":"10.1186/s40780-024-00333-1","url":null,"abstract":"<p><strong>Background: </strong>We evaluated the predictive factors for surgical site infections (SSIs) in elective colorectal cancer surgery and the role of antimicrobial stewardship (AS) pharmacists in modifying the clinical pathway.</p><p><strong>Main body: </strong>Between February 2017 and January 2022, 414 elective colorectal cancer surgeries were performed. The results of multivariate analysis by SSI incidence were adjusted odds ratio (aOR): 0.45; 95% confidence interval (CI): 0.22-0.96 (P = 0.039) for sex (female), aOR: 0.27; 95% CI: 0.13-0.58 (P < 0.001) for laparoscopy, aOR: 0.42; 95% CI: 0.19-0.91 (P = 0.029) for chemical bowel preparation. The median (interquartile range) postoperative length of stay was 12 (10.0-18.5) vs. 10 (9.0-13.0) days before and after the clinical pathway was modified (P < 0.001).</p><p><strong>Conclusion: </strong>The role of AS pharmacists was primarily to conduct a literature search to explore whether SSIs could be ameliorated by pharmacotherapy, coordinate the addition of chemical bowel preparation, and epidemiologically confirm their effectiveness.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"11"},"PeriodicalIF":1.0,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10875839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139905898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pembrolizumab-induced secondary adrenal insufficiency due to adrenocorticotrophic hormone deficiency in a patient with non-small-cell lung carcinoma: a case report. 非小细胞肺癌患者肾上腺皮质激素缺乏导致的 Pembrolizumab 引起的继发性肾上腺功能不全:病例报告。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-02-16 DOI: 10.1186/s40780-024-00332-2
Tatsuhiro Fujimiya, Kanako Azuma, Yuki Togashi, Koji Kuwata, Sakae Unezaki, Hironori Takeuchi

Background: Pembrolizumab can cause immune-related adverse events such as adrenal insufficiency (AI). However, there is no consensus regarding appropriate monitoring of adrenal function during subsequent chemotherapy in patients who have received immune checkpoint inhibitors (ICIs) such as pembrolizumab.

Case presentation: In this report, we discuss the case of a 60s-year-old male patient with non-small cell lung cancer receiving chemotherapy who developed secondary AI due to adrenocorticotrophic hormone (ACTH) deficiency 8 months after the discontinuation of pembrolizumab, which was 17 months after the initiation of pembrolizumab immunotherapy. After 5 months of chemotherapy, he developed fever and diarrhoea, after which chemotherapy was discontinued. Thereafter, he was hospitalised owing to the development of general fatigue and anorexia. Although cortisol and ACTH levels were not measured during chemotherapy, they were measured before hospitalisation, and secondary AI was suspected. After admission, a detailed endocrine workup was performed, and the patient was diagnosed with secondary AI due to ACTH deficiency. Treatment with hydrocortisone was initiated, which markedly improved his general fatigue and anorexia. The patient showed no evidence of progressive disease 9 months after the discontinuation of pembrolizumab.

Conclusions: Although rare, the possibility of AI should be considered in patients who have received ICIs when nonspecific symptoms develop during or after subsequent chemotherapy, and measurements of endocrine function (including cortisol and ACTH levels) should be performed.

背景Pembrolizumab 可导致免疫相关不良事件,如肾上腺功能不全(AI)。然而,对于接受免疫检查点抑制剂(ICIs)(如 Pembrolizumab)治疗的患者在后续化疗期间肾上腺功能的适当监测,目前尚未达成共识:在本报告中,我们讨论了一例接受化疗的 60 多岁男性非小细胞肺癌患者,他在停用 Pembrolizumab 8 个月后因肾上腺皮质激素(ACTH)缺乏而出现继发性 AI,此时距离 Pembrolizumab 免疫疗法的开始已有 17 个月。化疗 5 个月后,他出现发烧和腹泻,随后化疗停止。此后,他因全身乏力和厌食而住院治疗。虽然在化疗期间没有测量皮质醇和促肾上腺皮质激素水平,但在住院前进行了测量,并怀疑有继发性 AI。入院后,医生对患者进行了详细的内分泌检查,确诊患者因缺乏促肾上腺皮质激素(ACTH)而患有继发性 AI。患者开始接受氢化可的松治疗,这明显改善了他的全身乏力和厌食症状。停用彭博利珠单抗9个月后,患者没有出现疾病进展的迹象:尽管罕见,但接受过 ICIs 治疗的患者在化疗期间或化疗后出现非特异性症状时,应考虑到 AI 的可能性,并应测量内分泌功能(包括皮质醇和促肾上腺皮质激素水平)。
{"title":"Pembrolizumab-induced secondary adrenal insufficiency due to adrenocorticotrophic hormone deficiency in a patient with non-small-cell lung carcinoma: a case report.","authors":"Tatsuhiro Fujimiya, Kanako Azuma, Yuki Togashi, Koji Kuwata, Sakae Unezaki, Hironori Takeuchi","doi":"10.1186/s40780-024-00332-2","DOIUrl":"10.1186/s40780-024-00332-2","url":null,"abstract":"<p><strong>Background: </strong>Pembrolizumab can cause immune-related adverse events such as adrenal insufficiency (AI). However, there is no consensus regarding appropriate monitoring of adrenal function during subsequent chemotherapy in patients who have received immune checkpoint inhibitors (ICIs) such as pembrolizumab.</p><p><strong>Case presentation: </strong>In this report, we discuss the case of a 60s-year-old male patient with non-small cell lung cancer receiving chemotherapy who developed secondary AI due to adrenocorticotrophic hormone (ACTH) deficiency 8 months after the discontinuation of pembrolizumab, which was 17 months after the initiation of pembrolizumab immunotherapy. After 5 months of chemotherapy, he developed fever and diarrhoea, after which chemotherapy was discontinued. Thereafter, he was hospitalised owing to the development of general fatigue and anorexia. Although cortisol and ACTH levels were not measured during chemotherapy, they were measured before hospitalisation, and secondary AI was suspected. After admission, a detailed endocrine workup was performed, and the patient was diagnosed with secondary AI due to ACTH deficiency. Treatment with hydrocortisone was initiated, which markedly improved his general fatigue and anorexia. The patient showed no evidence of progressive disease 9 months after the discontinuation of pembrolizumab.</p><p><strong>Conclusions: </strong>Although rare, the possibility of AI should be considered in patients who have received ICIs when nonspecific symptoms develop during or after subsequent chemotherapy, and measurements of endocrine function (including cortisol and ACTH levels) should be performed.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"10"},"PeriodicalIF":1.0,"publicationDate":"2024-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10873928/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139746802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An evaluation of pharmacists' general attitudes, knowledge, and phobias regarding medications that include corticosteroids: a cross-sectional study. 评估药剂师对包括皮质类固醇在内的药物的一般态度、知识和恐惧症:一项横断面研究。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-02-01 DOI: 10.1186/s40780-024-00329-x
Muna Barakat, Samar Thiab, Rana Abu Farha, Anas O Alshweiki, Roa'a Thaher, Asem Alsughaier, Diana Malaeb

Background: Corticosteroid-containing medications are widely accessible in various forms, including topical, injectable, and inhaled formulations. Due to uncertain safety profiles, healthcare providers, including pharmacists, often express apprehension when dispensing these drugs. This cross-sectional study assesses the knowledge, attitudes, and phobia of Jordanian pharmacists regarding corticosteroid-containing medications.

Methods: Conducted through a self-administered online questionnaire.

Results: the study reveals that dermatological conditions and respiratory disorders are the primary indications for prescribing corticosteroid-containing drugs. The most reported side effects among pharmacists' patients include increased appetite, diabetes, and skin thinning. Pharmacists generally exhibit acceptable knowledge, with a median score of 9.0 out of 11.0 (IQR = 3.0). Over two-thirds of pharmacists (69.9%) achieve a high knowledge score (Bloom's cut-off point ≥ 8.8). However, only 55.7% are aware that corticosteroids may induce mood changes. High phobia scores, particularly concerning increased blood pressure and osteoporosis risks, indicate pharmacist reservations in corticosteroid dispensing. Interestingly, pharmacists in rural areas display lower knowledge scores, while those working outside community pharmacies exhibit lower phobia scores compared to their counterparts in urban areas and community pharmacies, respectively.

Conclusion: Despite generally good knowledge levels, the study underscores high phobia scores among Jordanian pharmacists regarding corticosteroid dispensing, particularly due to concerns about blood pressure elevation and osteoporosis risks. This suggests a potential need for targeted educational interventions and support systems to enhance pharmacist confidence and optimize corticosteroid usage while minimizing associated risks.

背景:含皮质类固醇的药物以各种形式广泛存在,包括外用、注射和吸入制剂。由于安全性不确定,包括药剂师在内的医疗服务提供者在配发这类药物时常常表示担忧。本横断面研究评估了约旦药剂师对含皮质类固醇药物的认识、态度和恐惧心理:结果:研究显示,皮肤病和呼吸系统疾病是处方含皮质类固醇药物的主要适应症。药剂师的病人报告最多的副作用包括食欲增加、糖尿病和皮肤变薄。药剂师的知识水平普遍可以接受,中位数为 9.0(满分 11.0)(IQR = 3.0)。超过三分之二的药剂师(69.9%)达到了知识高分(布卢姆分界点≥ 8.8)。然而,只有 55.7% 的药剂师知道皮质类固醇可能会引起情绪变化。高恐惧症得分,尤其是关于血压升高和骨质疏松风险的得分,表明药剂师对皮质类固醇的配药有所保留。有趣的是,与城市地区和社区药房的药剂师相比,农村地区药剂师的知识得分较低,而在社区药房以外工作的药剂师的恐惧症得分也较低:尽管药剂师的知识水平普遍较高,但这项研究强调了约旦药剂师对皮质类固醇配药的恐惧心理,尤其是对血压升高和骨质疏松症风险的担忧。这表明可能需要有针对性的教育干预措施和支持系统,以增强药剂师的信心,优化皮质类固醇的使用,同时将相关风险降至最低。
{"title":"An evaluation of pharmacists' general attitudes, knowledge, and phobias regarding medications that include corticosteroids: a cross-sectional study.","authors":"Muna Barakat, Samar Thiab, Rana Abu Farha, Anas O Alshweiki, Roa'a Thaher, Asem Alsughaier, Diana Malaeb","doi":"10.1186/s40780-024-00329-x","DOIUrl":"10.1186/s40780-024-00329-x","url":null,"abstract":"<p><strong>Background: </strong>Corticosteroid-containing medications are widely accessible in various forms, including topical, injectable, and inhaled formulations. Due to uncertain safety profiles, healthcare providers, including pharmacists, often express apprehension when dispensing these drugs. This cross-sectional study assesses the knowledge, attitudes, and phobia of Jordanian pharmacists regarding corticosteroid-containing medications.</p><p><strong>Methods: </strong>Conducted through a self-administered online questionnaire.</p><p><strong>Results: </strong>the study reveals that dermatological conditions and respiratory disorders are the primary indications for prescribing corticosteroid-containing drugs. The most reported side effects among pharmacists' patients include increased appetite, diabetes, and skin thinning. Pharmacists generally exhibit acceptable knowledge, with a median score of 9.0 out of 11.0 (IQR = 3.0). Over two-thirds of pharmacists (69.9%) achieve a high knowledge score (Bloom's cut-off point ≥ 8.8). However, only 55.7% are aware that corticosteroids may induce mood changes. High phobia scores, particularly concerning increased blood pressure and osteoporosis risks, indicate pharmacist reservations in corticosteroid dispensing. Interestingly, pharmacists in rural areas display lower knowledge scores, while those working outside community pharmacies exhibit lower phobia scores compared to their counterparts in urban areas and community pharmacies, respectively.</p><p><strong>Conclusion: </strong>Despite generally good knowledge levels, the study underscores high phobia scores among Jordanian pharmacists regarding corticosteroid dispensing, particularly due to concerns about blood pressure elevation and osteoporosis risks. This suggests a potential need for targeted educational interventions and support systems to enhance pharmacist confidence and optimize corticosteroid usage while minimizing associated risks.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"8"},"PeriodicalIF":1.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10832149/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139672049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Public hospital pharmacists' knowledge, attitudes, and practices for antibiotic stewardship implementation in Limpopo Province, South Africa. 南非林波波省公立医院药剂师在实施抗生素管理方面的知识、态度和实践。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-02-01 DOI: 10.1186/s40780-024-00331-3
Tiyani Comfort Mthombeni, Johanita Riétte Burger, Martha Susanna Lubbe, Marlene Julyan

Background: Hospital pharmacists are important in antibiotic stewardship programs (ASP), a global strategy to combat antibiotic resistance (ABR). South African public hospitals have limited ASP implementation. This study describes Limpopo Provincial Hospital pharmacists' knowledge, attitudes, and practice toward ASP implementation.

Method: A questionnaire to explore pharmacists' knowledge, attitudes and practices regarding ASP implementation comprised 43 questions hosted online. A link was sent by invitation e-mail to eligible respondents in November 2021. Five questions on respondents' demographics, 15 questions on ASP knowledge, 10 Likert scale questions on attitude, and 13 on ASP practices were included. Mean (standard deviation (SD)) knowledge and attitude scores and a median (interquartile range (IQR)) practice score was calculated. Associations between categorical variables were assessed using chi-square/Fisher's exact analysis (p < 0.05), with Cramér's V as effect size.

Results: The survey yielded 35 responses (13.1%). Twenty (57.1%) respondents were female. Seventeen (48.6%) respondents were between the ages of 31 and 40 years. The mean knowledge score of respondents was 9.8 (2.6) (N = 34), with knowledge gaps on One Health and socioeconomic determinates of ABR. Ten (29.6%) respondents thought One Health discouraged multi-sector collaboration, and nineteen (55.9%) respondents thought ASP was the only strategic response to ABR. Sixteen (47.1%) respondents did not know that poor access to clean water accelerates ABR and seventeen (50.0%) did not know that poverty could be a determinant for antibiotic use. The mean respondent attitude score was 8.0 (1.7) (N = 28). Twenty-seven (96.4%) respondents agreed that ASP was necessary and agreed to participate in ASP respectively. All 28 (100.0%) respondents agreed to lead an ASP. The median (IQR) respondents' practice score was - 2.0 (IQR: -6.0-5.8) (N = 16). Respondents were inconsistently (never, sometimes, every time) participating in multi-disciplinary forums (6/16, 37.5%) and expressed a desire for training (11/13, 84.6%) on ASP through in-service (7/27, 25.9%). Respondents thought ASP training should include medical officers (12/29, 41.4%) and nurses (9/29, 31.8%). Knowledge score was associated with gender (p = 0.048; V = 0.416) and attitude score (p = 0.013; V = 0.556).

Conclusion: Our study found pharmacists had good knowledge and a positive attitude toward ASP implementation but poor ASP practices. A multi-disciplinary in-service training could address identified knowledge and practice gaps.

背景:医院药剂师在抗生素管理计划 (ASP) 中发挥着重要作用,这是一项对抗抗生素耐药性 (ABR) 的全球战略。南非公立医院对 ASP 的实施力度有限。本研究介绍了林波波省立医院药剂师对实施 ASP 的认识、态度和做法:为了解药剂师对实施 ASP 的认识、态度和做法,我们在线发放了一份调查问卷,其中包括 43 个问题。问卷链接于 2021 年 11 月通过邀请电子邮件发送给符合条件的受访者。其中包括 5 个关于受访者人口统计学的问题、15 个关于 ASP 知识的问题、10 个关于态度的李克特量表问题以及 13 个关于 ASP 实践的问题。计算了知识和态度得分的平均值(标准差 (SD))以及实践得分的中位数(四分位距 (IQR))。分类变量之间的关联采用卡方/费舍尔精确分析法进行评估(P 结果:调查共收到 35 份回复(13.1%)。20名(57.1%)受访者为女性。17(48.6%)名受访者的年龄在 31 至 40 岁之间。受访者的平均知识分数为 9.8 (2.6) (N = 34),在 "一体健康 "和 ABR 的社会经济决定因素方面存在知识差距。10名(29.6%)受访者认为 "一体健康 "不鼓励多部门合作,19名(55.9%)受访者认为联系学校项目是应对 ABR 的唯一战略对策。16(47.1%)名受访者不知道清洁水的匮乏会加速 ABR,17(50.0%)名受访者不知道贫困可能是抗生素使用的一个决定因素。受访者态度的平均得分为 8.0 (1.7) (N = 28)。27名受访者(96.4%)分别同意有必要开展 ASP 并同意参与 ASP。所有 28 位(100.0%)受访者都同意领导一次联系学校项目。受访者实践得分的中位数(IQR)为-2.0(IQR:-6.0-5.8)(N = 16)。受访者参加多学科论坛的次数不一致(从不、有时、每次)(6/16,37.5%),并表示希望通过在职培训(7/27,25.9%)获得关于 ASP 的培训(11/13,84.6%)。受访者认为 ASP 培训应包括医务人员(12/29,41.4%)和护士(9/29,31.8%)。知识得分与性别(p = 0.048;V = 0.416)和态度得分(p = 0.013;V = 0.556)有关:我们的研究发现,药剂师对实施 ASP 有良好的认识和积极的态度,但 ASP 实践较差。多学科在职培训可弥补已发现的知识和实践差距。
{"title":"Public hospital pharmacists' knowledge, attitudes, and practices for antibiotic stewardship implementation in Limpopo Province, South Africa.","authors":"Tiyani Comfort Mthombeni, Johanita Riétte Burger, Martha Susanna Lubbe, Marlene Julyan","doi":"10.1186/s40780-024-00331-3","DOIUrl":"10.1186/s40780-024-00331-3","url":null,"abstract":"<p><strong>Background: </strong>Hospital pharmacists are important in antibiotic stewardship programs (ASP), a global strategy to combat antibiotic resistance (ABR). South African public hospitals have limited ASP implementation. This study describes Limpopo Provincial Hospital pharmacists' knowledge, attitudes, and practice toward ASP implementation.</p><p><strong>Method: </strong>A questionnaire to explore pharmacists' knowledge, attitudes and practices regarding ASP implementation comprised 43 questions hosted online. A link was sent by invitation e-mail to eligible respondents in November 2021. Five questions on respondents' demographics, 15 questions on ASP knowledge, 10 Likert scale questions on attitude, and 13 on ASP practices were included. Mean (standard deviation (SD)) knowledge and attitude scores and a median (interquartile range (IQR)) practice score was calculated. Associations between categorical variables were assessed using chi-square/Fisher's exact analysis (p < 0.05), with Cramér's V as effect size.</p><p><strong>Results: </strong>The survey yielded 35 responses (13.1%). Twenty (57.1%) respondents were female. Seventeen (48.6%) respondents were between the ages of 31 and 40 years. The mean knowledge score of respondents was 9.8 (2.6) (N = 34), with knowledge gaps on One Health and socioeconomic determinates of ABR. Ten (29.6%) respondents thought One Health discouraged multi-sector collaboration, and nineteen (55.9%) respondents thought ASP was the only strategic response to ABR. Sixteen (47.1%) respondents did not know that poor access to clean water accelerates ABR and seventeen (50.0%) did not know that poverty could be a determinant for antibiotic use. The mean respondent attitude score was 8.0 (1.7) (N = 28). Twenty-seven (96.4%) respondents agreed that ASP was necessary and agreed to participate in ASP respectively. All 28 (100.0%) respondents agreed to lead an ASP. The median (IQR) respondents' practice score was - 2.0 (IQR: -6.0-5.8) (N = 16). Respondents were inconsistently (never, sometimes, every time) participating in multi-disciplinary forums (6/16, 37.5%) and expressed a desire for training (11/13, 84.6%) on ASP through in-service (7/27, 25.9%). Respondents thought ASP training should include medical officers (12/29, 41.4%) and nurses (9/29, 31.8%). Knowledge score was associated with gender (p = 0.048; V = 0.416) and attitude score (p = 0.013; V = 0.556).</p><p><strong>Conclusion: </strong>Our study found pharmacists had good knowledge and a positive attitude toward ASP implementation but poor ASP practices. A multi-disciplinary in-service training could address identified knowledge and practice gaps.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"9"},"PeriodicalIF":1.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10832237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139671998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In-vitro evaluation of Indigofera heterantha extracts for antibacterial, antifungal and anthelmintic activities. 靛蓝提取物抗菌、抗真菌和驱虫活性的体外评价。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-24 DOI: 10.1186/s40780-024-00328-y
Showkat Ahmad Bhat, Mohammed Iqbal Zargar, Shahid Ud Din Wani, Ishfaq Mohiuddin, Mubashir Hussain Masoodi, Faiyaz Shakeel, Mohammad Ali, Seema Mehdi

Background: Multidrug-resistant bacterial strains cause several serious infections that can be fatal, such as Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacteriaceae (often referred to as ESKAPE pathogens). Since ancient times, several indigenous medical systems in India have utilized diverse medicinal plants (approximately 80,000 species) as conventional treatments for a variety of illnesses. A member of the Fabaceae family, also referred to as "Himalayan indigo," Indigofera heterantha Wall, is well known for its therapeutic properties.

Methods: The present study investigated the antibacterial, antifungal and antihelmintic properties of the roots, bark, leaves, and flowers of I. heterantha from the Kashmir Himalayas. The effectiveness of the extracts against bacteria, fungi, and earthworms. Three of the tested organisms for bacteria were ESKAPE pathogens, as they are responsible for creating fatal bacterial infections. The antifungal potency of I. heterantha aqueous and methanolic extracts was evaluated using the Agar Well Diffusion Assay. The antihelmintic activity was carried out on an adult Pheretima posthuma Indian earth worm, which shares physiological and anatomical similarities with human intestinal roundworm parasites.

Results: The methanolic extracts of root and bark have shown prominent activity against all bacterial strains, whereas aqueous extracts of flower, root, and leaves have shown promising activity against Staphylococcus aureus. The aqueous extract demonstrated good activity against S. cerevisiae at a concentration of 200 mg/ml with a zone of inhibition of 16 mm, while the methanolic extract displayed comparable activity against the fungal strains. The remaining two strains, P. crysogenum and A. fumigatus, were only moderately active in response to the extracts. All the extracts have shown anthelmintic activity except aqueous flower.

Conclusion: These results will pave the way for the bioassay-guided isolation of bioactive constituents that may act as hits for further development as potential antibacterial agents against drug-resistant microbial and helminthic infections.

背景:耐多药细菌菌株可导致多种严重感染,如粪肠球菌、金黄色葡萄球菌、肺炎克雷伯氏菌、鲍曼不动杆菌、铜绿假单胞菌和肠杆菌科细菌(通常称为 ESKAPE 病原体)。自古以来,印度的一些本土医疗体系就利用各种药用植物(约有 80,000 种)作为治疗各种疾病的常规方法。一种被称为 "喜马拉雅蓝靛 "的豆科植物 Indigofera heterantha Wall 以其治疗特性而闻名:本研究调查了来自克什米尔喜马拉雅山的 Indigofera heterantha 的根、树皮、叶和花的抗菌、抗真菌和驱虫特性。萃取物对细菌、真菌和蚯蚓的功效。细菌测试生物中有三种是 ESKAPE 病原体,因为它们是造成致命细菌感染的罪魁祸首。使用琼脂井扩散试验评估了 I. heterantha 水提取物和甲醇提取物的抗真菌效力。对印度蚯蚓成虫(Pheretima posthuma Indian earth worm)的抗蠕虫活性进行了研究,该成虫与人类肠道蛔虫在生理和解剖结构上有相似之处:结果:根和树皮的甲醇提取物对所有细菌菌株都有显著的活性,而花、根和叶的水提取物对金黄色葡萄球菌有很好的活性。在 200 毫克/毫升的浓度下,水提取物对酿酒葡萄球菌有很好的活性,抑制区为 16 毫米,而甲醇提取物对真菌菌株也有类似的活性。其余两种菌株,即冰冻菌和烟曲霉,对萃取物只有中等程度的活性。除花水剂外,所有提取物都具有抗蠕虫活性:这些结果将为在生物测定指导下分离生物活性成分铺平道路,这些生物活性成分可作为抗耐药性微生物和蠕虫感染的潜在抗菌剂进一步开发。
{"title":"In-vitro evaluation of Indigofera heterantha extracts for antibacterial, antifungal and anthelmintic activities.","authors":"Showkat Ahmad Bhat, Mohammed Iqbal Zargar, Shahid Ud Din Wani, Ishfaq Mohiuddin, Mubashir Hussain Masoodi, Faiyaz Shakeel, Mohammad Ali, Seema Mehdi","doi":"10.1186/s40780-024-00328-y","DOIUrl":"10.1186/s40780-024-00328-y","url":null,"abstract":"<p><strong>Background: </strong>Multidrug-resistant bacterial strains cause several serious infections that can be fatal, such as Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacteriaceae (often referred to as ESKAPE pathogens). Since ancient times, several indigenous medical systems in India have utilized diverse medicinal plants (approximately 80,000 species) as conventional treatments for a variety of illnesses. A member of the Fabaceae family, also referred to as \"Himalayan indigo,\" Indigofera heterantha Wall, is well known for its therapeutic properties.</p><p><strong>Methods: </strong>The present study investigated the antibacterial, antifungal and antihelmintic properties of the roots, bark, leaves, and flowers of I. heterantha from the Kashmir Himalayas. The effectiveness of the extracts against bacteria, fungi, and earthworms. Three of the tested organisms for bacteria were ESKAPE pathogens, as they are responsible for creating fatal bacterial infections. The antifungal potency of I. heterantha aqueous and methanolic extracts was evaluated using the Agar Well Diffusion Assay. The antihelmintic activity was carried out on an adult Pheretima posthuma Indian earth worm, which shares physiological and anatomical similarities with human intestinal roundworm parasites.</p><p><strong>Results: </strong>The methanolic extracts of root and bark have shown prominent activity against all bacterial strains, whereas aqueous extracts of flower, root, and leaves have shown promising activity against Staphylococcus aureus. The aqueous extract demonstrated good activity against S. cerevisiae at a concentration of 200 mg/ml with a zone of inhibition of 16 mm, while the methanolic extract displayed comparable activity against the fungal strains. The remaining two strains, P. crysogenum and A. fumigatus, were only moderately active in response to the extracts. All the extracts have shown anthelmintic activity except aqueous flower.</p><p><strong>Conclusion: </strong>These results will pave the way for the bioassay-guided isolation of bioactive constituents that may act as hits for further development as potential antibacterial agents against drug-resistant microbial and helminthic infections.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"7"},"PeriodicalIF":1.2,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809583/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139546757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of hospital pharmacists' activities using additional reimbursement for infection prevention as an indicator in small and medium-sized hospitals. 以中小型医院预防感染的额外报销为指标,评估医院药剂师的活动。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-10 DOI: 10.1186/s40780-023-00327-5
Yuichi Tasaka, Takeshi Uchikura, Shiro Hatakeyama, Daisuke Kikuchi, Masami Tsuchiya, Ryohkan Funakoshi, Taku Obara
<p><strong>Background: </strong>Hospitals in Japan established the healthcare delivery system from FY 2018 to 2021 by acquiring an additional reimbursement for infection prevention (ARIP) of category 1 or 2. However, research on outcomes of ARIP applications related to the practice of hospital pharmacists is scarce.</p><p><strong>Methods: </strong>This study assessed the activities performed by hospital pharmacists in hospitals with 100 to 299 beds, using ARIP acquirement as an indicator, using data from an annual questionnaire survey conducted in 2020 by the Japanese Society of Hospital Pharmacists on the status of hospital pharmacy departments. Out of the survey items, this study used those related to hospital functions, number of beds, number of pharmacists, whether the hospital is included in the diagnosis procedure combination (DPC) system, average length of stay, and nature of work being performed in the analysis. The relationship between the number of beds per pharmacist and state of implementation of pharmacist services or the average length of hospital stay was considered uncorrelated when the absolute value of the correlation coefficient was within 0-0.2, whereas the relationship was considered to have a weak, moderate, or strong correlation when the absolute value ranged at 0.2-0.4, 0.4-0.7, or 0.7-1, respectively.</p><p><strong>Results: </strong>Responses were received from 3612 (recovery rate: 43.6%) hospitals. Of these, 210 hospitals meeting the criteria for ARIP 1 with 100-299 beds, and 245 hospitals meeting the criteria for ARIP 2 with 100-299 beds, were included in our analysis. There was a significant difference in the number of pharmacists, with a larger number in ARIP 1 hospitals. For the pharmacist services, significant differences were observed, with a more frequency in ARIP 1 hospitals in pharmaceutical management and guidance to pre-hospitalization patients, sterile drug processing of injection drugs and therapeutic drug monitoring. In DPC hospitals with ARIP 1 (173 hospitals) and 2 (105 hospitals), the average number of beds per pharmacist was 21.7 and 24.7, respectively, while the average length of stay was 14.3 and 15.4 d, respectively. Additionally, a weak negative correlation was observed between the number of pharmacist services with "Fairly well" or "Often" and the number of beds per pharmacist for both ARIP 1 (R = -0.207) and ARIP 2 (R = -0.279) DPC hospitals. Furthermore, a weak correlation (R = 0.322) between the average number of beds per pharmacist and the average length of hospital stay was observed for ARIP 2 hospitals.</p><p><strong>Conclusions: </strong>Our results suggest that lower beds per pharmacist might lead to improved pharmacist services in 100-299 beds DPC hospitals with ARIP 1 or 2. The promotion of proactive efforts in hospital pharmacist services and fewer beds per pharmacist may relate to shorter hospital stays especially in small and medium-sized hospitals with ARIP 2 when ARIP acquisition was
背景:日本医院通过获得 1 类或 2 类感染预防额外报销(ARIP),建立了 2018 至 2021 财年的医疗服务体系。然而,与医院药剂师实践相关的 ARIP 申请结果研究却很少:本研究利用日本医院药剂师协会于 2020 年对医院药剂部门的状况进行的年度问卷调查数据,以获得 ARIP 为指标,评估了拥有 100-299 张病床的医院药剂师所开展的活动。在调查项目中,本研究使用了与医院功能、床位数、药剂师人数、医院是否纳入诊断程序组合(DPC)系统、平均住院日和工作性质相关的项目进行分析。当相关系数的绝对值在 0-0.2 范围内时,每位药剂师的床位数与药剂师服务的实施情况或平均住院时间之间的关系被认为是不相关的;而当相关系数的绝对值分别在 0.2-0.4、0.4-0.7 或 0.7-1 范围内时,这种关系被认为是弱、中或强相关的:共收到 3612 家医院的回复(回复率:43.6%)。其中,210 家符合 ARIP 1 标准且拥有 100-299 张病床的医院和 245 家符合 ARIP 2 标准且拥有 100-299 张病床的医院被纳入我们的分析范围。药剂师人数存在明显差异,ARIP 1 医院的药剂师人数更多。在药剂师服务方面,我们观察到了明显的差异,ARIP 1 医院在入院前病人的药物管理和指导、注射药物的无菌药物处理和治疗药物监测方面的频率更高。在拥有 ARIP 1(173 家医院)和 ARIP 2(105 家医院)的 DPC 医院中,每名药剂师的平均床位数分别为 21.7 张和 24.7 张,平均住院时间分别为 14.3 天和 15.4 天。此外,在 ARIP 1(R = -0.207)和 ARIP 2(R = -0.279)的 DPC 医院中,"相当好 "或 "经常 "的药剂师服务数量与每位药剂师的床位数之间存在微弱的负相关。此外,在 ARIP 2 医院中,每位药剂师的平均床位数与平均住院时间之间存在微弱的相关性(R = 0.322):我们的研究结果表明,在拥有 ARIP 1 或 2 的 100-299 张床位的 DPC 医院中,每位药剂师的床位数越少,药剂师的服务就越好。促进医院药剂师服务的积极努力以及减少每位药剂师的床位数可能会缩短住院时间,尤其是在以 ARIP 获取作为指标的 ARIP 2 中小型医院。这些发现可能有助于在未来加快医院药剂师参与感染控制的步伐。
{"title":"Evaluation of hospital pharmacists' activities using additional reimbursement for infection prevention as an indicator in small and medium-sized hospitals.","authors":"Yuichi Tasaka, Takeshi Uchikura, Shiro Hatakeyama, Daisuke Kikuchi, Masami Tsuchiya, Ryohkan Funakoshi, Taku Obara","doi":"10.1186/s40780-023-00327-5","DOIUrl":"10.1186/s40780-023-00327-5","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Hospitals in Japan established the healthcare delivery system from FY 2018 to 2021 by acquiring an additional reimbursement for infection prevention (ARIP) of category 1 or 2. However, research on outcomes of ARIP applications related to the practice of hospital pharmacists is scarce.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This study assessed the activities performed by hospital pharmacists in hospitals with 100 to 299 beds, using ARIP acquirement as an indicator, using data from an annual questionnaire survey conducted in 2020 by the Japanese Society of Hospital Pharmacists on the status of hospital pharmacy departments. Out of the survey items, this study used those related to hospital functions, number of beds, number of pharmacists, whether the hospital is included in the diagnosis procedure combination (DPC) system, average length of stay, and nature of work being performed in the analysis. The relationship between the number of beds per pharmacist and state of implementation of pharmacist services or the average length of hospital stay was considered uncorrelated when the absolute value of the correlation coefficient was within 0-0.2, whereas the relationship was considered to have a weak, moderate, or strong correlation when the absolute value ranged at 0.2-0.4, 0.4-0.7, or 0.7-1, respectively.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Responses were received from 3612 (recovery rate: 43.6%) hospitals. Of these, 210 hospitals meeting the criteria for ARIP 1 with 100-299 beds, and 245 hospitals meeting the criteria for ARIP 2 with 100-299 beds, were included in our analysis. There was a significant difference in the number of pharmacists, with a larger number in ARIP 1 hospitals. For the pharmacist services, significant differences were observed, with a more frequency in ARIP 1 hospitals in pharmaceutical management and guidance to pre-hospitalization patients, sterile drug processing of injection drugs and therapeutic drug monitoring. In DPC hospitals with ARIP 1 (173 hospitals) and 2 (105 hospitals), the average number of beds per pharmacist was 21.7 and 24.7, respectively, while the average length of stay was 14.3 and 15.4 d, respectively. Additionally, a weak negative correlation was observed between the number of pharmacist services with \"Fairly well\" or \"Often\" and the number of beds per pharmacist for both ARIP 1 (R = -0.207) and ARIP 2 (R = -0.279) DPC hospitals. Furthermore, a weak correlation (R = 0.322) between the average number of beds per pharmacist and the average length of hospital stay was observed for ARIP 2 hospitals.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Our results suggest that lower beds per pharmacist might lead to improved pharmacist services in 100-299 beds DPC hospitals with ARIP 1 or 2. The promotion of proactive efforts in hospital pharmacist services and fewer beds per pharmacist may relate to shorter hospital stays especially in small and medium-sized hospitals with ARIP 2 when ARIP acquisition was","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"6"},"PeriodicalIF":1.0,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10782696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139417310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Pharmaceutical Health Care and Sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1